Markus Goebel

Direttore/Membro del Consiglio presso OSE IMMUNOTHERAPEUTICS

Health Technology

Consumer Services

Retail Trade

Profilo

Markus Goebel has held various director positions in multiple pharmaceutical and biotech companies.
He is currently a Director at FoldRx.
Pharmaceuticals LLC, Sorbent Therapeutics, Inc., EraGen Biosciences, Inc., Merganser Biotech, Inc., and OSE Immunotherapeutics SA. In the past, he has also served as a Director at Sirtris Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Zikani Therapeutics, Inc., Locus Pharmaceuticals, Inc., LigoCyte Pharmaceuticals, Inc., Intellikine LLC, Novartis Services, Inc., Novartis Venture Funds (USA), eFFECTOR Therapeutics Operations, Inc., and ESCAPE Bio, Inc. Dr. Goebel holds an MBA from Henley Management College and a doctorate from Ludwig-Maximilians-Universität München.

Posizioni attive di Markus Goebel

Società	Posizione	Inizio
OSE IMMUNOTHERAPEUTICS	Direttore/Membro del Consiglio	19/06/2024
Merganser Biotech, Inc. Merganser Biotech, Inc. BiotechnologyHealth Technology Provides biotechnology services	Direttore/Membro del Consiglio	-
FoldRx Pharmaceuticals LLC FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services	Direttore/Membro del Consiglio	-
EraGen Biosciences, Inc. EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets molecular diagnostic testing products	Direttore/Membro del Consiglio	01/01/2004
Sorbent Therapeutics, Inc. Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases	Direttore/Membro del Consiglio	-

Tutte le posizioni attive di Markus Goebel

Precedenti posizioni note di Markus Goebel

Società	Posizione	Fine
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Investitore di Private Equity	30/04/2019
LigoCyte Pharmaceuticals, Inc. LigoCyte Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Developed vaccines and monoclonal antibody therapeutics	Direttore/Membro del Consiglio	16/04/2014
Locus Pharmaceuticals, Inc. Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services	Direttore/Membro del Consiglio	-
Novartis Services, Inc. Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company	Presidente	29/01/2010
░░░░░░░░░░░ ░░░	░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░	-

Vedi nel dettaglio l'esperienza di Markus Goebel

Formazione di Markus Goebel

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Markus Goebel

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	17
FoldRx Pharmaceuticals LLC FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services	Health Technology
Sirtris Pharmaceuticals, Inc. Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs and pharmaceuticals	Health Technology
Sorbent Therapeutics, Inc. Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases	Health Technology
Ra Pharmaceuticals, Inc. Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease	Health Technology
Zikani Therapeutics, Inc. Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens	Retail Trade
Locus Pharmaceuticals, Inc. Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services	Health Technology
EraGen Biosciences, Inc. EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets molecular diagnostic testing products	Health Technology
Henley Management College Henley Management College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Ludwig-Maximilians-Universität München Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
LigoCyte Pharmaceuticals, Inc. LigoCyte Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Developed vaccines and monoclonal antibody therapeutics	Health Technology
Intellikine LLC Intellikine LLC Pharmaceuticals: MajorHealth Technology Develops and manufactures small molecule drugs for the treatment of cancer	Health Technology
Novartis Services, Inc. Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company	Health Technology
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Finance
eFFECTOR Therapeutics Operations, Inc. eFFECTOR Therapeutics Operations, Inc. BiotechnologyHealth Technology Operates a clinical-stage biopharmaceutical company that develops oncology drugs	Health Technology
Merganser Biotech, Inc. Merganser Biotech, Inc. BiotechnologyHealth Technology Provides biotechnology services	Health Technology
OSE Immunotherapeutics SA OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers	Health Technology
ESCAPE Bio, Inc. ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease	Health Technology